HMGB1 and neoplasm: Consistent with our in vitro findings, simvastatin-treated mice showed significantly higher serum levels of HMGB1 and a greater proportion of CRT+ tumor cells compared to controls (Fig. 7i, j), along with increased recruitment of conventional DCs to the tumor (Fig. 7k).